Refine
Has Fulltext
- yes (33)
Is part of the Bibliography
- yes (33)
Year of publication
Document Type
- Journal article (33)
Language
- English (33) (remove)
Keywords
- radiotherapy (8)
- prostate cancer (6)
- DNA damage (3)
- IGRT (3)
- hypofractionation (3)
- long-term outcome (3)
- rectal cancer (3)
- toxicity (3)
- DNA repair (2)
- Glioblastoma (2)
- Halcyon (2)
- IMRT (2)
- VMAT (2)
- adaptation (2)
- cancer (2)
- cone beam CT (2)
- image-guided radiation therapy (2)
- radiosensitivity (2)
- radiotherapy (RT) (2)
- salvage radiotherapy (2)
- simultaneous integrated boost (2)
- 4D-MRI (1)
- ATM (1)
- Adaptation (1)
- Akt (1)
- BRAF (1)
- Brain cancer (1)
- CD133 (1)
- CIED malfunction; pacemaker (PM) (1)
- CNS cancer (1)
- Corticosteroids (1)
- DNA double strand breaks (1)
- DNA repair protraction (1)
- DNA-PK (1)
- DNS-Reparatur (1)
- DNS-Schädigung (1)
- Glioma stem cells (1)
- High grade glioma (1)
- IR (1)
- NSCLC (1)
- NVP-BEZ235 (1)
- Nestin (1)
- Non-rigid image registration (1)
- Novel PI3K (1)
- Osteopontin (1)
- PI3K (1)
- PSMA (1)
- PSMA PET/CT (1)
- PTEN (1)
- Peripheral blood lymphocytes (1)
- Prostate carcinoma (1)
- Radiosensitivity (1)
- Radiotherapy (1)
- Radiotherapy treatment planning (1)
- Respiratory induced tumor motion (1)
- Synergy (1)
- TGFβ1 (1)
- Temozolomide (1)
- \(\gamma\)h2ax (1)
- accelerated hyperfractionation (1)
- acute toxicity (1)
- adaptive radiotherapy (1)
- adrenal tumours (1)
- adrenocortical carcinoma (ACC) (1)
- altered fractionation (1)
- apoptosis (1)
- auto-planning (1)
- autophagy (1)
- battery depletion (1)
- biochemical relapse free survival (1)
- blood lymphocytes (1)
- cardiac implantable electronic devices (CIED) (1)
- cardiac resynchronization therapy (CRT) (1)
- chemoradiotherapy (1)
- dabrafenib (1)
- deformable image registration (1)
- dominant intraprostatic lesion (1)
- dose accumulation (1)
- dose escalation (1)
- dose evaluation (1)
- dose to OARs (1)
- double arc (1)
- external beam radiotherapy (EBRT) (1)
- foci (1)
- full arc (1)
- glioblastoma (1)
- head and neck cancer (1)
- head and neck squamous cell carcinoma (1)
- high-dose-rate (HDR) brachytherapy (1)
- high-dose-rate brachytherapy boost (1)
- histone H2AX (1)
- hypoxia (1)
- implantable cardioverter defibrillator (ICD) (1)
- in vivo (1)
- individual radiosensitivity (1)
- intensity-modulated radiation therapy (1)
- intensity-modulated radiotherapy (1)
- irradiation (1)
- local control (1)
- lung cancer (1)
- mTOR Inhibitor (1)
- macroscopic recurrence (1)
- megavoltage computed-tomography (1)
- metastasis-directed therapy (1)
- multimodal therapy (1)
- multiple brain metastases (1)
- neck cancer (1)
- neoadjuvant (1)
- oligorecurrence (1)
- oral mucositis (1)
- osteopontin (1)
- outcomes research (1)
- oxidative DNA damage (1)
- partial arc (1)
- perioperative changes (1)
- peripheral blood lymphocytes (1)
- phosphorylation (1)
- plan comparison (1)
- propensity score matching (1)
- prostate Imaging Reporting and Data System (1)
- radiation (1)
- radiosensibility (1)
- re-irradiation (1)
- re-planning (1)
- repair (1)
- risk (1)
- risk score (1)
- setup verification (1)
- single arc (1)
- strategies (1)
- survival (1)
- temozolomide (1)
- thoracic cancer (1)
- transperineal ultrasound (1)
- treatment plan (1)
- variability (1)
- vemurafenib (1)
- whole breast irradiation (1)
- zinc oxide nanoparticles (1)
Institute
- Klinik und Poliklinik für Strahlentherapie (32)
- Comprehensive Cancer Center Mainfranken (3)
- Klinik und Poliklinik für Nuklearmedizin (3)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (2)
- Medizinische Klinik und Poliklinik I (2)
- Pathologisches Institut (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Frauenklinik und Poliklinik (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Medizinische Strahlenkunde und Zellforschung (1)
Background and Purpose
The standard treatment of glioblastoma patients consists of surgery followed by normofractionated radiotherapy (NFRT) with concomitant and adjuvant temozolomide chemotherapy. Whether accelerated hyperfractionated radiotherapy (HFRT) yields comparable results to NFRT in combination with temozolomide has only sparsely been investigated. The objective of this study was to compare NFRT with HFRT in a multicenter analysis.
Materials and Methods
A total of 484 glioblastoma patients from four centers were retrospectively pooled and analyzed. Three-hundred-ten and 174 patients had been treated with NFRT (30 × 1.8 Gy or 30 × 2 Gy) and HFRT (37 × 1.6 Gy or 30 × 1.8 Gy twice/day), respectively. The primary outcome of interest was overall survival (OS) which was correlated with patient-, tumor- and treatment-related variables via univariable and multivariable Cox frailty models. For multivariable modeling, missing covariates were imputed using multiple imputation by chained equations, and a sensitivity analysis was performed on the complete-cases-only dataset.
Results
After a median follow-up of 15.7 months (range 0.8-88.6 months), median OS was 16.9 months (15.0-18.7 months) in the NFRT group and 14.9 months (13.2-17.3 months) in the HFRT group (p = 0.26). In multivariable frailty regression, better performance status, gross-total versus not gross-total resection, MGMT hypermethylation, IDH mutation, smaller planning target volume and salvage therapy were significantly associated with longer OS (all p < 0.01). Treatment differences (HFRT versus NFRT) had no significant effect on OS in either univariable or multivariable analysis.
Conclusions
Since HFRT with temozolomide was not associated with worse OS, we assume HFRT to be a potential option for patients wishing to shorten their treatment time.
Background
The prognostic value of histone γ-H2AX and 53BP1 proteins to predict the radiotherapy (RT) outcome of patients with rectal carcinoma (RC) was evaluated in a prospective study. High expression of the constitutive histone γ-H2AX is indicative of defective DNA repair pathway and/or genomic instability, whereas 53BP1 (p53-binding protein 1) is a conserved checkpoint protein with properties of a DNA double-strand breaks sensor.
Methods
Using fluorescence microscopy, we assessed spontaneous and radiation-induced foci of γ-H2AX and 53BP1 in peripheral blood mononuclear cells derived from unselected RC patients (n = 53) undergoing neoadjuvant chemo- and RT. Cells from apparently healthy donors (n = 12) served as references.
Results
The γ-H2AX assay of in vitro irradiated lymphocytes revealed significantly higher degree of DNA damage in the group of unselected RC patients with respect to the background, initial (0.5 Gy, 30 min) and residual (0.5 Gy and 2 Gy, 24 h post-radiation) damage compared to the control group. Likewise, the numbers of 53BP1 foci analyzed in the samples from 46 RC patients were significantly higher than in controls except for the background DNA damage. However, both markers were not able to predict tumor stage, gastrointestinal toxicity or tumor regression after curative RT. Interestingly, the mean baseline and induced DNA damage was found to be lower in the group of RC patients with tumor stage IV (n = 7) as compared with the stage III (n = 35). The difference, however, did not reach statistical significance, apparently, because of the limited number of patients.
Conclusions
The study shows higher expression of γ-H2AX and 53BP1 foci in rectal cancer patients compared with healthy individuals. Yet the data in vitro were not predictive in regard to the radiotherapy outcome.
Background: Adaptive Radiotherapy aims to identify anatomical deviations during a radiotherapy course and modify the treatment plan to maintain treatment objectives. This requires regions of interest (ROIs) to be defined using the most recent imaging data. This study investigates the clinical utility of using deformable image registration (DIR) to automatically propagate ROIs.
Methods: Target (GTV) and organ-at-risk (OAR) ROIs were non-rigidly propagated from a planning CT scan to a per-treatment CT scan for 22 patients. Propagated ROIs were quantitatively compared with expert physician-drawn ROIs on the per-treatment scan using Dice scores and mean slicewise Hausdorff distances, and center of mass distances for GTVs. The propagated ROIs were qualitatively examined by experts and scored based on their clinical utility.
Results: Good agreement between the DIR-propagated ROIs and expert-drawn ROIs was observed based on the metrics used. 94% of all ROIs generated using DIR were scored as being clinically useful, requiring minimal or no edits. However, 27% (12/44) of the GTVs required major edits.
Conclusion: DIR was successfully used on 22 patients to propagate target and OAR structures for ART with good anatomical agreement for OARs. It is recommended that propagated target structures be thoroughly reviewed by the treating physician.